Literature DB >> 31987361

Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

A Vogel, A Cervantes, I Chau, B Daniele, J M Llovet, T Meyer, J-C Nault, U Neumann, J Ricke, B Sangro, P Schirmacher, C Verslype, C J Zech, D Arnold, E Martinelli.   

Abstract

Entities:  

Year:  2019        PMID： 31987361     DOI： 10.1093/annonc/mdy510

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  12 in total

Review 1.  Modern therapeutic approaches for the treatment of malignant liver tumours.

Authors:  Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-17       Impact factor: 46.802

2.  Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis.

Authors:  Jaekyung Cheon; Hong Jae Chon; Yeonghak Bang; Neung Hwa Park; Jung Woo Shin; Kang Mo Kim; Han Chu Lee; Jooho Lee; Changhoon Yoo; Baek-Yeol Ryoo
Journal:  Liver Cancer       Date:  2020-07-29       Impact factor: 11.740

3.  Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.

Authors:  Ruiqing Chen; Ye Li; Ke Song; Lingbing Li; Chenyu Shen; Pengkai Ma; Zhijun Wang
Journal:  J Gastrointest Oncol       Date:  2022-04

4.  Medical ozone induces proliferation and migration inhibition through ROS accumulation and PI3K/AKT/NF-κB suppression in human liver cancer cells in vitro.

Authors:  J Li; T Zeng; S Tang; M Zhong; Q Huang; X Li; X He
Journal:  Clin Transl Oncol       Date:  2021-04-05       Impact factor: 3.405

5.  Identification of Biomarkers Related to Immune Cell Infiltration in Hepatocellular Carcinoma Using Gene Co-Expression Network.

Authors:  Wanbang Zhou; Yiyang Chen; Ruixing Luo; Zifan Li; Guanwei Jiang; Xi Ou
Journal:  Pathol Oncol Res       Date:  2021-04-02       Impact factor: 3.201

6.  The oncogene Mct-1 promotes progression of hepatocellular carcinoma via enhancement of Yap-mediated cell proliferation.

Authors:  Wenjie Yang; Yong Ni; Shikun Yang; Yang Ji; Xinchen Yang; Feng Cheng; Xuehao Wang; Feng Zhang; Jianhua Rao
Journal:  Cell Death Discov       Date:  2021-03-22

Review 7.  Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control.

Authors:  Pierre Nahon; Erwan Vo Quang; Nathalie Ganne-Carrié
Journal:  J Clin Med       Date:  2021-01-19       Impact factor: 4.241

Review 8.  Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points.

Authors:  Janina Świderska; Mateusz Kozłowski; Sebastian Kwiatkowski; Aneta Cymbaluk-Płoska
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

9.  Prognostic Value of Preoperative Prognostic Nutritional Index and Body Mass Index Combination in Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization.

Authors:  Shengwei Li; Jin-He Guo; Jian Lu; Chao Wang; Hao Wang
Journal:  Cancer Manag Res       Date:  2021-02-17       Impact factor: 3.989

Review 10.  The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.

Authors:  Patrizia Leone; Antonio Giovanni Solimando; Rossella Fasano; Antonella Argentiero; Eleonora Malerba; Alessio Buonavoglia; Luigi Giovanni Lupo; Valli De Re; Nicola Silvestris; Vito Racanelli
Journal:  Vaccines (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.